I-Semaglutide ayikho nje ukunciphisa umzimba

I-Semaglutide iziyobisi ezinciphisa i-glucose eyenziwe nguNovo Nordisk kunyango lwe-2 yeswekile. NgoJuni 2021, i-FDA yavuma i-Semaglutide yokuthengisa njengeyeza lokulahlekelwa kwesisindo (igama lokuthengisa i-Wegovy). Ichiza liyi-glucagon-like peptide 1 (GLP-1) i-receptor agonist enokulinganisa imiphumo yayo, ukunciphisa indlala, kwaye ngaloo ndlela inciphisa ukutya kunye nekhalori, ngoko iyasebenza ekulahlekeni kwesisindo.

Ngaphandle kokusetyenziswa ukunyanga uhlobo lwe-2 yeswekile kunye nokukhuluphala, i-Semaglutide ifunyenwe ukukhusela impilo ye-cardiovascular, ukunciphisa umngcipheko womhlaza, kunye nokunceda ukuyeka ukusela. Ukongezelela, izifundo ezimbini zakutshanje zibonise ukuba i-Semaglutide inokunciphisa umngcipheko wesifo esingapheliyo sesifo kunye nesifo se-Alzheimer.

Izifundo zangaphambili zibonise ukuba ukulahlekelwa kwesisindo kunokunciphisa iimpawu ze-knee osteoarthritis (kubandakanywa nokunciphisa intlungu). Nangona kunjalo, iziphumo ze-GLP-1 receptor agonist yokulahlekelwa kweziyobisi ezifana ne-Semaglutide kwiziphumo ze-knee osteoarthritis kubantu abatyebileyo abazange bafunde ngokupheleleyo.

Ngo-Oktobha 30, i-2024, abaphandi abavela kwiYunivesithi yaseCopenhagen kunye neNovo Nordisk bapapashe iphepha lophando elinesihloko esithi: Kanye-ngeVeki ye-Semaglutide kuBantu abane-Obesity kunye ne-Knee Osteoarthritis kwi-New England Journal of Medicine (NEJM), iphephancwadi lezonyango eliphezulu lamazwe ngamazwe.

Olu pho nonongo lweklinikhi lubonise ukuba i-semaglutide inokunciphisa kakhulu ubunzima kunye nokunciphisa kakhulu intlungu ebangelwa ukukhuluphala kwe-knee arthritis (i-analgesic effect ilingana ne-opioids), kunye nokuphucula amandla abo okuthatha inxaxheba kwimidlalo. Eli lixesha lokuqala ukuba uhlobo olutsha lweyeza lokulahlekelwa kwesisindo, i-GLP-1 receptor agonist, iqinisekisiwe ukunyanga i-arthritis.